Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Innovent Biologics (IVBXF) Stock Price & Analysis

IVBXF Stock Chart & Stats

$9.90-$1.40(-12.39%)
At close: 4:00 PM EDT
$10$12.5$153 Aug17 Aug31 Aug15 Sep28 Sep12 Oct26 Oct
Day’s Range
$9.90 - $11.10
52-Week Range
$9.07 - $15.01
Previous Close
$11.30
Volume
539
Average Volume (3M)
2,326
Market Cap
$17.76B
Enterprise Value
$122.92B
Total Cash (Recent Filing)
$20.00B
Total Debt (Recent Filing)
$2.32B
Price to Earnings (P/E)
95.6
Beta
-0.04
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
0.17
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Profit Inflection

The 2025 improvement shows stronger commercial scale and a meaningful move toward profitability. If revenue growth and positive earnings persist, Innovent can fund development internally, strengthen its market position, and improve operating leverage across its biologics portfolio.

High Gross Margin

A gross margin of approximately 86.5% indicates substantial value capture from Innovent’s biologic products and provides a strong base for covering research, commercial, and administrative costs. Continued margin resilience would support profitability as sales expand.

Conservative Balance Sheet

Low leverage and a larger equity base give Innovent financial flexibility to continue investing in clinical development, manufacturing, and commercialization. The stronger capital position also reduces balance-sheet pressure while the company builds a more durable earnings record.

Bears Say

Unproven Profitability Durability

The return to profit is encouraging, but the preceding multi-year period of operating losses shows that earnings durability has not yet been established. Continued execution will be necessary to demonstrate that the 2025 improvement reflects a lasting business model shift.

Historically Inconsistent Cash Flow

The sharp 2025 cash-flow improvement strengthens the current financial profile, but the earlier pattern of negative and volatile cash generation indicates uneven conversion of business activity into cash. A sustained track record is needed before the latest step-up can be viewed as fully durable.

Modest Net Profitability

The gap between very high gross margin and relatively modest net profitability suggests that operating and other expenses still absorb a substantial portion of product economics. This limits earnings resilience and leaves less room for setbacks in development or commercialization.

Innovent Biologics News

IVBXF FAQ

What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was $9.07 and its highest was $15.01 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is $17.76B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 150 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported $0.105 earnings per share for the quarter, beating the consensus estimate of $0.071 by $0.035.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.17.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,746,918,300 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of $0.105 in its last earnings report, beating expectations of $0.071. Following the earnings report the stock price went down -2.278%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in IVBXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology